Ingporn Jiamset
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ingporn Jiamset has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Jitti Hanprasertpong
Department of Medical Research and Innovation, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok 10300, Thailand
8 shared publications - Kulisara Nanthamongkolkul
Department of Obstetrics and Gynecology, Faculty of Medicine Prince of Songkla University Songkhla Thailand
3 shared publications - Rakchai Buhachat
Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
3 shared publications Alan Geater
2 shared publications- Alan Geater
Department of Epidemiology, Faculty of Medicine Prince of Songkla University Songkhla Thailand
2 shared publications Athithan Rattanaburi
Department of Obstetrics and Gynecology, Faculty of Medicine Prince of Songkla University Songkhla Thailand
2 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Springer Nature in BMC Women's Health
Prognostic significance of post-treatment total lymphocyte count in locally advanced cervical cancer after definitive chemoradiotherapy
Background: Studies evaluating the impact of lymphopenia after the completion of chemoradiotherapy on survival outcomes in patients with cervical cancer have been inconsistent, limited by small sample sizes, and rarely focused on post-treatment total lymphocyte count (TLC). Consequently, this study evaluated the association between post-treatment TLC and survival outcomes in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy. Methods: We retrospectively reviewed the data of 298 patients with locally advanced cervical cancer who showed a definite complete response to concurrent chemoradiotherapy between January 2011 and December 2018. We obtained clinicopathological and TLC data at the end of treatment and at 1-year after treatment. The associations between TLC, overall survival (OS), and disease-free survival (DFS) were evaluated. Results: Patients with post-treatment TLC ≥ 500 cells/mm 3 at the end of treatment tended to have better DFS and OS than those with post-treatment TLC < 500 cells/mm 3 , although the differences did not reach statistical significance ( p = 0.11 and 0.14, respectively). At the 1-year landmark, the OS and DFS rates were significantly higher in patients with post-treatment TLC ≥ 1000 cells/mm 3 than in those with TLC < 1000 cells/mm 3 (OS: 76.0% vs. 48.4%, p = 0.00026; DFS: 74.5% vs. 44.3%, p = 0.00034). Moreover, post-treatment TLC ≥ 1000 cells/mm 3 was identified as an independent favorable prognostic factor for OS and DFS in both univariate (HR 0.36, 95% CI 0.21–0.64, p < 0.001; and HR 0.37, 95% CI 0.21–0.65, p < 0.001, respectively) and multivariate analyses (HR 0.41, 95% CI 0.22–0.74, p = 0.003; and HR 0.42, 95% CI 0.23–0.76, p = 0.004, respectively). Conclusion: While TLC at the end of treatment showed no significant association, persistent lymphopenia at 1-year post-treatment emerged as an independent poor prognostic factor for survival in locally advanced cervical cancer.
- 25 September 2026
- Published by Springer Nature in BMC Women's Health
Open AccessPrognostic significance of post-treatment total lymphocyte count in locally advanced cervical cancer after definitive chemoradiotherapy
Background: Studies evaluating the impact of lymphopenia after the completion of chemoradiotherapy on survival outcomes in patients with cervical cancer have been inconsistent, limited by small sample sizes, and rarely focused on post-treatment total lymphocyte count (TLC). Consequently, this study evaluated the association between post-treatment TLC and survival outcomes in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy. Methods: We retrospectively reviewed the data of 298 patients with locally advanced cervical cancer who showed a definite complete response to concurrent chemoradiotherapy between January 2011 and December 2018. We obtained clinicopathological and TLC data at the end of treatment and at 1-year after treatment. The associations between TLC, overall survival (OS), and disease-free survival (DFS) were evaluated. Results: Patients with post-treatment TLC ≥ 500 cells/mm 3 at the end of treatment tended to have better DFS and OS than those with post-treatment TLC < 500 cells/mm 3 , although the differences did not reach statistical significance ( p = 0.11 and 0.14, respectively). At the 1-year landmark, the OS and DFS rates were significantly higher in patients with post-treatment TLC ≥ 1000 cells/mm 3 than in those with TLC < 1000 cells/mm 3 (OS: 76.0% vs. 48.4%, p = 0.00026; DFS: 74.5% vs. 44.3%, p = 0.00034). Moreover, post-treatment TLC ≥ 1000 cells/mm 3 was identified as an independent favorable prognostic factor for OS and DFS in both univariate (HR 0.36, 95% CI 0.21–0.64, p < 0.001; and HR 0.37, 95% CI 0.21–0.65, p < 0.001, respectively) and multivariate analyses (HR 0.41, 95% CI 0.22–0.74, p = 0.003; and HR 0.42, 95% CI 0.23–0.76, p = 0.004, respectively). Conclusion: While TLC at the end of treatment showed no significant association, persistent lymphopenia at 1-year post-treatment emerged as an independent poor prognostic factor for survival in locally advanced cervical cancer.
- 14 April 2026
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 175 (1) , 300-309
Neutrophil‐to‐lymphocyte ratio as a prognostic marker for survival outcomes in women with cervical cancer and HIV infection
Objective: This study aimed to determine the prognostic value of neutrophil‐to‐lymphocyte ratio (NLR) in women with cervical cancer infected with HIV. Methods: This retrospective cohort study included women with cervical cancer with HIV infection who underwent primary treatment at a tertiary hospital in southern Thailand between 2005 and 2019. Overall survival (OS) and progression‐free survival (PFS) were analyzed using the Kaplan–Meier method. Univariate and multivariate Cox regression analyses were used to determine the independent factors associated with OS and PFS. Results: Among 100 patients (median follow‐up time 37.63 months), the 5‐year OS and PFS rates were 64.5% (95% confidence interval [CI]: 55.0–75.6) and 58.2% (95% CI: 48.6–69.6), respectively. In the multivariate analysis, high NLR (hazard ratio [HR]: 3.53, 95% CI: 1.58–7.91, P = 0.002) and low equivalent total dose in 2 Gy fractions at point A (HR 2.14, 95% CI: 1.02–4.49, P = 0.045) were independent predictors of worse OS, while poor performance status (HR 6.73, 95% CI: 1.93–23.56, P = 0.003), adenocarcinoma histology (HR 3.32, 95% CI: 1.43–7.72, P = 0.005), and high NLR (HR 4.04, 95% CI: 1.87–8.73, P < 0.001) were independent predictors of worse PFS. Conclusion: High NLR independently predicts poor OS and PFS in women with cervical cancer with HIV.
- 14 April 2026
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 175 (1) , 300-309
Neutrophil‐to‐lymphocyte ratio as a prognostic marker for survival outcomes in women with cervical cancer and HIV infection
Objective: This study aimed to determine the prognostic value of neutrophil‐to‐lymphocyte ratio (NLR) in women with cervical cancer infected with HIV. Methods: This retrospective cohort study included women with cervical cancer with HIV infection who underwent primary treatment at a tertiary hospital in southern Thailand between 2005 and 2019. Overall survival (OS) and progression‐free survival (PFS) were analyzed using the Kaplan–Meier method. Univariate and multivariate Cox regression analyses were used to determine the independent factors associated with OS and PFS. Results: Among 100 patients (median follow‐up time 37.63 months), the 5‐year OS and PFS rates were 64.5% (95% confidence interval [CI]: 55.0–75.6) and 58.2% (95% CI: 48.6–69.6), respectively. In the multivariate analysis, high NLR (hazard ratio [HR]: 3.53, 95% CI: 1.58–7.91, P = 0.002) and low equivalent total dose in 2 Gy fractions at point A (HR 2.14, 95% CI: 1.02–4.49, P = 0.045) were independent predictors of worse OS, while poor performance status (HR 6.73, 95% CI: 1.93–23.56, P = 0.003), adenocarcinoma histology (HR 3.32, 95% CI: 1.43–7.72, P = 0.005), and high NLR (HR 4.04, 95% CI: 1.87–8.73, P < 0.001) were independent predictors of worse PFS. Conclusion: High NLR independently predicts poor OS and PFS in women with cervical cancer with HIV.
- Open Access
- 15 July 2025
- Published by Korean Society of Obstetrics and Gynecology in Obstetrics & Gynecology Science
- Vol. 68 (4) , 283-292
Overall survival after progression in patients with uterine carcinosarcoma: a single-center retrospective cohort study
ObjectiveTo investigate 2-year overall survival (OS) after progression in patients with uterine carcinosarcoma (UCS).MethodsThis retrospective descriptive cohort study included patients diagnosed with progressive UCS at all stages, who underwent surgical staging with or without adjuvant therapy between January 2002 and December 2022. Clinicopathological characteristics, including recurrence patterns, were assessed using descriptive statistics, Fisher’s exact test, and the chi-squared test. Prognostic factors and OS after progression were analyzed using the Cox proportional hazards model and Kaplan-Meier method, respectively.ResultsFifty-four patients (mean age, 61 years) were eligible for analysis. During primary treatment, 40 patients underwent optimal surgery, 44 received adjuvant chemotherapy with or without radiotherapy, and 43 developed progressive disease within the first 2 years (median progression-free interval: 10.5 months). Overall, 74.07% of patients developed distant or combined metastases. During salvage treatment, 22 patients received chemotherapy, 11 received a combination of chemotherapy and radiotherapy, and five underwent radiotherapy alone. The median follow-up period was 18 months, with a 2-year OS rate of 20% post-progression. Multivariate analysis revealed that leukocytosis at progression was associated with decreased survival (hazard ratio [HR], 5.98; 95% confidence interval [CI], 2.33-15.3; P<0.001). Notably, optimal primary surgery (HR, 0.31; 95% CI, 0.13-0.72; P=0.006) and chemoradiotherapy as salvage treatment (HR, 0.23; 95% CI, 0.08-0.7; P=0.009) significantly improved survival.ConclusionPatients with progressive UCS have poor OS. Optimal surgery as primary treatment combined with salvage chemoradiotherapy improves post-progression survival. Leukocytosis during disease progression significantly affects survival outcomes.
- 15 July 2025
- Published by Korean Society of Obstetrics and Gynecology in Obstetrics & Gynecology Science
- Vol. 68 (4) , 283-292
Open AccessOverall survival after progression in patients with uterine carcinosarcoma: a single-center retrospective cohort study
ObjectiveTo investigate 2-year overall survival (OS) after progression in patients with uterine carcinosarcoma (UCS).MethodsThis retrospective descriptive cohort study included patients diagnosed with progressive UCS at all stages, who underwent surgical staging with or without adjuvant therapy between January 2002 and December 2022. Clinicopathological characteristics, including recurrence patterns, were assessed using descriptive statistics, Fisher’s exact test, and the chi-squared test. Prognostic factors and OS after progression were analyzed using the Cox proportional hazards model and Kaplan-Meier method, respectively.ResultsFifty-four patients (mean age, 61 years) were eligible for analysis. During primary treatment, 40 patients underwent optimal surgery, 44 received adjuvant chemotherapy with or without radiotherapy, and 43 developed progressive disease within the first 2 years (median progression-free interval: 10.5 months). Overall, 74.07% of patients developed distant or combined metastases. During salvage treatment, 22 patients received chemotherapy, 11 received a combination of chemotherapy and radiotherapy, and five underwent radiotherapy alone. The median follow-up period was 18 months, with a 2-year OS rate of 20% post-progression. Multivariate analysis revealed that leukocytosis at progression was associated with decreased survival (hazard ratio [HR], 5.98; 95% confidence interval [CI], 2.33-15.3; P<0.001). Notably, optimal primary surgery (HR, 0.31; 95% CI, 0.13-0.72; P=0.006) and chemoradiotherapy as salvage treatment (HR, 0.23; 95% CI, 0.08-0.7; P=0.009) significantly improved survival.ConclusionPatients with progressive UCS have poor OS. Optimal surgery as primary treatment combined with salvage chemoradiotherapy improves post-progression survival. Leukocytosis during disease progression significantly affects survival outcomes.
- 4 July 2024
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 167 (2) , 736-742
Comparative study of the prevalence of organ injury in placenta accreta spectrum disorder between posterior colpotomy and conventional peripartum hysterectomies at a single referral center in southern Thailand
Objective: To compare the prevalence of adjacent organ injury in placenta accreta spectrum disorder (PAS) between the posterior colpotomy approach and conventional peripartum hysterectomy.Methods: This retrospective study analyzed the data of pregnant women diagnosed with PAS who underwent peripartum hysterectomy at Songklanagarind Hospital between January 2006 and December 2021. The patients were divided into two groups: posterior colpotomy and conventional approaches. The characteristics and surgical and obstetric outcomes were compared. Univariate and multivariate logistic regression was used to identify factors and risk of organ injury.Results: Among 174 patients, 64 underwent conventional peripartum hysterectomy, and 110 underwent the posterior colpotomy approach. The overall incidence of adjacent organ injury was 17.82%. Organ injury prevalence was lower in the posterior colpotomy group (10%) than in the conventional group (31.25%), with no difference in operative time. Multivariate analysis showed that posterior colpotomy reduced adjacent organ injury (odds ratio [OR] 0.18, 95% confidence interval [CI] 0.06–0.54, P = 0.002). Placenta percreta was associated with increased injury risk (OR 6.83, 95% CI 2.53–18.44, P < 0.002). Subgroup analysis showed that the posterior approach reduced bladder injury in placenta increta (OR 0.14, 95% CI 0.04–0.57, P = 0.003) and percreta (OR 0.19, 95% CI 0.05–0.77, P = 0.017).Conclusion: Compared with conventional peripartum hysterectomy, the posterior colpotomy approach in patients with PAS reduced the risk of adjacent organ injury, particularly for placenta increta and percreta. This technique should be considered in PAS cases, but further investigations with a prospective study design are needed.
- 4 July 2024
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 167 (2) , 736-742
Comparative study of the prevalence of organ injury in placenta accreta spectrum disorder between posterior colpotomy and conventional peripartum hysterectomies at a single referral center in southern Thailand
Objective: To compare the prevalence of adjacent organ injury in placenta accreta spectrum disorder (PAS) between the posterior colpotomy approach and conventional peripartum hysterectomy.Methods: This retrospective study analyzed the data of pregnant women diagnosed with PAS who underwent peripartum hysterectomy at Songklanagarind Hospital between January 2006 and December 2021. The patients were divided into two groups: posterior colpotomy and conventional approaches. The characteristics and surgical and obstetric outcomes were compared. Univariate and multivariate logistic regression was used to identify factors and risk of organ injury.Results: Among 174 patients, 64 underwent conventional peripartum hysterectomy, and 110 underwent the posterior colpotomy approach. The overall incidence of adjacent organ injury was 17.82%. Organ injury prevalence was lower in the posterior colpotomy group (10%) than in the conventional group (31.25%), with no difference in operative time. Multivariate analysis showed that posterior colpotomy reduced adjacent organ injury (odds ratio [OR] 0.18, 95% confidence interval [CI] 0.06–0.54, P = 0.002). Placenta percreta was associated with increased injury risk (OR 6.83, 95% CI 2.53–18.44, P < 0.002). Subgroup analysis showed that the posterior approach reduced bladder injury in placenta increta (OR 0.14, 95% CI 0.04–0.57, P = 0.003) and percreta (OR 0.19, 95% CI 0.05–0.77, P = 0.017).Conclusion: Compared with conventional peripartum hysterectomy, the posterior colpotomy approach in patients with PAS reduced the risk of adjacent organ injury, particularly for placenta increta and percreta. This technique should be considered in PAS cases, but further investigations with a prospective study design are needed.
- 19 January 2024
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 165 (3) , 1210-1217
Effect of time interval between surgery and the initiation of adjuvant therapy on the oncologic outcomes of early‐stage endometrial cancer
Objective: To identify the impact of time interval between surgery and initial adjuvant radiotherapy on oncologic outcomes in early‐stage endometrial cancer.Methods: This retrospective cohort study included patients with stage I/II endometrial cancer who underwent surgical staging and adjuvant therapy at Songklanagarind Hospital from January 1, 2007, to December 31, 2017. Patients were categorized into two groups: TI P = 0.008) and 3‐year OS (95.5% vs 83.2%; P = 0.012) in patients with TI P = 0.012) and an inferior OS (HR 3.80; 95% CI: 1.23–11.69; P = 0.02).Conclusion: A delay in the TI between surgery and the initiation of adjuvant radiotherapy of ≥6 weeks negatively affected the oncologic outcomes in early‐stage endometrial cancer.
- 19 January 2024
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 165 (3) , 1210-1217
Effect of time interval between surgery and the initiation of adjuvant therapy on the oncologic outcomes of early‐stage endometrial cancer
Objective: To identify the impact of time interval between surgery and initial adjuvant radiotherapy on oncologic outcomes in early‐stage endometrial cancer.Methods: This retrospective cohort study included patients with stage I/II endometrial cancer who underwent surgical staging and adjuvant therapy at Songklanagarind Hospital from January 1, 2007, to December 31, 2017. Patients were categorized into two groups: TI P = 0.008) and 3‐year OS (95.5% vs 83.2%; P = 0.012) in patients with TI P = 0.012) and an inferior OS (HR 3.80; 95% CI: 1.23–11.69; P = 0.02).Conclusion: A delay in the TI between surgery and the initiation of adjuvant radiotherapy of ≥6 weeks negatively affected the oncologic outcomes in early‐stage endometrial cancer.
- 20 September 2023
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 164 (3) , 1080-1085
Comparative outcomes between transvaginal endoscopic hysterectomy and total laparoscopic hysterectomy in patients with benign uterine disease: A single‐center, retrospective, cohort, interrupted time‐series study
Objectives: To compare the surgical outcomes of total laparoscopic hysterectomy (TLH) and transvaginal endoscopic hysterectomy (TVEH) for benign uterine diseases.Methods: This retrospective, cohort, interrupted time‐series study included patients who underwent TLH between January 2013 and September 2016 and TVEH between October 2016 and June 2020. Median difference regression was used to compare the hospital length of stay (LOS) and operative time between the groups. Risk difference regression was used to analyze the proportion of patients who developed postoperative fever or vaginal stump infection.Results: Of the total 171 patients enrolled, 101 and 70 underwent TVEH and TLH, respectively. The mean ages of patients in the TVEH and TLH groups were 46.49 and 46.17 years, respectively. No conversion was observed. Ureteric injury occurred in one patient in the TVEH group, whereas there was no organ injury in any of the patients in the TLH group. Compared with those in the TLH group, patients in the TVEH group had a significantly shorter median operative time, shorter hospital LOS, lower morphine use, and lower postoperative febrile morbidity rates. However, no significant difference was observed in the rate of vaginal stump infection between the groups.Conclusion: Given the shorter operative time, shorter hospital LOS, less febrile morbidity, and lower morphine use in patients with TVEH than in those with TLH, TVEH should be considered as an alternative hysterectomy procedure for benign uterine diseases.
- 20 September 2023
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 164 (3) , 1080-1085
Comparative outcomes between transvaginal endoscopic hysterectomy and total laparoscopic hysterectomy in patients with benign uterine disease: A single‐center, retrospective, cohort, interrupted time‐series study
Objectives: To compare the surgical outcomes of total laparoscopic hysterectomy (TLH) and transvaginal endoscopic hysterectomy (TVEH) for benign uterine diseases.Methods: This retrospective, cohort, interrupted time‐series study included patients who underwent TLH between January 2013 and September 2016 and TVEH between October 2016 and June 2020. Median difference regression was used to compare the hospital length of stay (LOS) and operative time between the groups. Risk difference regression was used to analyze the proportion of patients who developed postoperative fever or vaginal stump infection.Results: Of the total 171 patients enrolled, 101 and 70 underwent TVEH and TLH, respectively. The mean ages of patients in the TVEH and TLH groups were 46.49 and 46.17 years, respectively. No conversion was observed. Ureteric injury occurred in one patient in the TVEH group, whereas there was no organ injury in any of the patients in the TLH group. Compared with those in the TLH group, patients in the TVEH group had a significantly shorter median operative time, shorter hospital LOS, lower morphine use, and lower postoperative febrile morbidity rates. However, no significant difference was observed in the rate of vaginal stump infection between the groups.Conclusion: Given the shorter operative time, shorter hospital LOS, less febrile morbidity, and lower morphine use in patients with TVEH than in those with TLH, TVEH should be considered as an alternative hysterectomy procedure for benign uterine diseases.
- Open Access
- 15 May 2023
- Published by Korean Society of Obstetrics and Gynecology in Obstetrics & Gynecology Science
- Vol. 66 (3) , 198-207
A personalized nomogram for predicting 3-year overall survival of patients with uterine carcinosarcoma in a tertiary care hospital in Southern Thailand
Objective To develop a nomogram for predicting 3-year overall survival (OS) and outcomes of surgically staged patients with uterine carcinosarcomas (UCS).Methods This retrospective study analyzed the clinicopathological characteristics, treatment data, and oncological outcomes of 69 patients diagnosed with UCS between January 2002 and September 2018. Significant prognostic factors for OS were identified and integrated to develop a nomogram. Concordance probability (CP) was used as a precision measure. The model was internally validated using bootstrapping samples to correct overfitting.Results The median follow-up time was 19.4 months (range, 0.77-106.13 months). The 3-year OS was 41.8% (95% confidence interval [CI], 29.9-58.3%). The International Federation of Gynecology and Obstetrics (FIGO) stage and adjuvant chemotherapy were independent factors for OS. The CP of the nomogram integrating with body mass index (BMI), FIGO stage, and adjuvant chemotherapy was 0.72 (95% CI, 0.70-0.75). In addition, the calibration curves for the probability of 3-year OS demonstrated good agreement between the nomogram-predicted and observed data.Conclusion The established nomogram using BMI, FIGO stage, and adjuvant chemotherapy accurately predicted the 3-year OS of patients with UCS. The nomogram was useful for patient counselling and deciding on follow-up strategies.
- 15 May 2023
- Published by Korean Society of Obstetrics and Gynecology in Obstetrics & Gynecology Science
- Vol. 66 (3) , 198-207
Open AccessA personalized nomogram for predicting 3-year overall survival of patients with uterine carcinosarcoma in a tertiary care hospital in Southern Thailand
Objective To develop a nomogram for predicting 3-year overall survival (OS) and outcomes of surgically staged patients with uterine carcinosarcomas (UCS).Methods This retrospective study analyzed the clinicopathological characteristics, treatment data, and oncological outcomes of 69 patients diagnosed with UCS between January 2002 and September 2018. Significant prognostic factors for OS were identified and integrated to develop a nomogram. Concordance probability (CP) was used as a precision measure. The model was internally validated using bootstrapping samples to correct overfitting.Results The median follow-up time was 19.4 months (range, 0.77-106.13 months). The 3-year OS was 41.8% (95% confidence interval [CI], 29.9-58.3%). The International Federation of Gynecology and Obstetrics (FIGO) stage and adjuvant chemotherapy were independent factors for OS. The CP of the nomogram integrating with body mass index (BMI), FIGO stage, and adjuvant chemotherapy was 0.72 (95% CI, 0.70-0.75). In addition, the calibration curves for the probability of 3-year OS demonstrated good agreement between the nomogram-predicted and observed data.Conclusion The established nomogram using BMI, FIGO stage, and adjuvant chemotherapy accurately predicted the 3-year OS of patients with UCS. The nomogram was useful for patient counselling and deciding on follow-up strategies.
- Open Access
- 17 March 2023
- Published by Wiley in Case Reports in Obstetrics and Gynecology
- Vol. 2023, 1-7
Secondary Erythrocytosis Associated with Uterine Myoma Is Rare but Should Be of Concern
Myomatous erythrocytosis syndrome (MES) is a rare gynecological condition, defined by the presence of the clinical triad of erythrocytosis, uterine fibroids, and normalization of red blood cell counts after the surgical removal of uterine fibroids. Herein, we report the case of a woman, in the postmenopausal stage, with the clinical triad of MES. She had a history of erythrocytosis of unknown etiology and underwent phlebotomy for a year prior to visiting our hospital. Pre-operative hemoglobin (Hb) level, hematocrit (Hct) level, and red blood cell (RBC) count were 18.1g/dL, 56.1, and 6.52 million cells/μL, respectively. She underwent exploratory laparotomy, transabdominal hysterectomy, and bilateral salpingo-oophorectomy. The operative findings revealed a large uterine myoma, and the pathology result was compatible with uterine leiomyoma. All hematologic parameters returned to the normal range on post-operative day 1. Her hematologic parameters returned to normal values 4 weeks after surgery with a Hb level of 13.5g/dL, Hct level of 41.2, and RBC count of 4.92 million cells/μL. The exact pathophysiology of this condition remains unknown. However, surgical removal of uterine myoma is the mainstay of treatment. Despite the rarity of this condition, its diagnosis should be considered in patients presenting with erythrocytosis and uterine masses.
- 17 March 2023
- Published by Wiley in Case Reports in Obstetrics and Gynecology
- Vol. 2023, 1-7
Open AccessSecondary Erythrocytosis Associated with Uterine Myoma Is Rare but Should Be of Concern
Myomatous erythrocytosis syndrome (MES) is a rare gynecological condition, defined by the presence of the clinical triad of erythrocytosis, uterine fibroids, and normalization of red blood cell counts after the surgical removal of uterine fibroids. Herein, we report the case of a woman, in the postmenopausal stage, with the clinical triad of MES. She had a history of erythrocytosis of unknown etiology and underwent phlebotomy for a year prior to visiting our hospital. Pre-operative hemoglobin (Hb) level, hematocrit (Hct) level, and red blood cell (RBC) count were 18.1g/dL, 56.1, and 6.52 million cells/μL, respectively. She underwent exploratory laparotomy, transabdominal hysterectomy, and bilateral salpingo-oophorectomy. The operative findings revealed a large uterine myoma, and the pathology result was compatible with uterine leiomyoma. All hematologic parameters returned to the normal range on post-operative day 1. Her hematologic parameters returned to normal values 4 weeks after surgery with a Hb level of 13.5g/dL, Hct level of 41.2, and RBC count of 4.92 million cells/μL. The exact pathophysiology of this condition remains unknown. However, surgical removal of uterine myoma is the mainstay of treatment. Despite the rarity of this condition, its diagnosis should be considered in patients presenting with erythrocytosis and uterine masses.
- 7 February 2023
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 162 (1) , 317-324
Impact of appendectomy of a grossly normal appendix on the survival outcomes of mucinous ovarian carcinomas in a tertiary hospital
Objective: To evaluate the survival outcomes of appendectomy for a grossly normal appendix in patients with mucinous ovarian carcinomas.Methods: Retrospective cohort study. Patients with mucinous ovarian carcinomas with grossly normal appendices who underwent primary surgery between 2002 and 2022 were enrolled. The overall survival (OS) and progression‐free survival (PFS) of appendectomy and non‐appendectomy groups were analyzed using the Kaplan–Meier method and compared using the log‐rank test. Univariate and multivariate Cox regression analyses were used to determine the independent factors associated with OS and PFS.Results: Of 192 patients, appendectomy was performed in 138 (71.9%). Three (1.6%) patients had primary appendiceal tumors and two (1.0%) had appendiceal metastases of ovarian origin. The median follow‐up time was 68.8 months. The OS and PFS were better in patients in the appendectomy group than in those in the non‐appendectomy group (5‐year OS: 80.72% vs. 65.05%, P = 0.012; 5‐year PFS: 76.32% vs. 58.60%, P = 0.020). Independent factors associated with poor OS and PFS were no omentectomy, peritoneal seeding, and advanced International Federation of Gynecology and Obstetrics (FIGO) stage.Conclusion: Appendectomy of a grossly normal appendix was not an independent prognostic factor for OS and PFS in patients with mucinous ovarian carcinomas.
- 7 February 2023
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 162 (1) , 317-324
Impact of appendectomy of a grossly normal appendix on the survival outcomes of mucinous ovarian carcinomas in a tertiary hospital
Objective: To evaluate the survival outcomes of appendectomy for a grossly normal appendix in patients with mucinous ovarian carcinomas.Methods: Retrospective cohort study. Patients with mucinous ovarian carcinomas with grossly normal appendices who underwent primary surgery between 2002 and 2022 were enrolled. The overall survival (OS) and progression‐free survival (PFS) of appendectomy and non‐appendectomy groups were analyzed using the Kaplan–Meier method and compared using the log‐rank test. Univariate and multivariate Cox regression analyses were used to determine the independent factors associated with OS and PFS.Results: Of 192 patients, appendectomy was performed in 138 (71.9%). Three (1.6%) patients had primary appendiceal tumors and two (1.0%) had appendiceal metastases of ovarian origin. The median follow‐up time was 68.8 months. The OS and PFS were better in patients in the appendectomy group than in those in the non‐appendectomy group (5‐year OS: 80.72% vs. 65.05%, P = 0.012; 5‐year PFS: 76.32% vs. 58.60%, P = 0.020). Independent factors associated with poor OS and PFS were no omentectomy, peritoneal seeding, and advanced International Federation of Gynecology and Obstetrics (FIGO) stage.Conclusion: Appendectomy of a grossly normal appendix was not an independent prognostic factor for OS and PFS in patients with mucinous ovarian carcinomas.
- Open Access
- 1 January 2021
- Published by XMLink
- p. O35
The impact of appendectomy in grossly normal appendix on the survival outcomes among mucinous borderline ovarian tumors and mucinous ovarian carcinomas, in a tertiary hospital
- 1 January 2021
- Published by XMLink
- p. O35
Open AccessThe impact of appendectomy in grossly normal appendix on the survival outcomes among mucinous borderline ovarian tumors and mucinous ovarian carcinomas, in a tertiary hospital